Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Humira® (adalimumab) – Expanded indication
October 16, 2018 - The FDA approved AbbVie’s Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in patients ≥ 12 years of age.
